US biotech 23andMe hits new lows as Sequoia Capital sells down stake
红杉资本减持股份，美国生物技术公司23andMe股价再创新低

Former investors and board members reduce holdings in the once much-hyped genetics-testing group
前投资者和董事会成员减持这家曾备受瞩目的基因测试集团的股票。